Craig A. Wheeler has served as a member of our Board since June 2016. He is currently President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also serves on the board of directors. Mr. Wheeler led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX® and once-daily COPAXONE®. Prior to Momenta, Craig worked at Chiron Corporation as President, Chiron BioPharmaceuticals (now Novartis Vaccines ↦ Diagnostics). Prior to joining Chiron, Craig was a senior member of The Boston Consulting Group’s health care practice. Mr. Wheeler also worked for Merck’s MSDRL research unit, where he served as a senior engineer in process development and at Hybritech as a financial analyst. Mr. Wheeler previously served for nine years as the Chairman of the Board of Avanir Pharmaceuticals where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion. He also served as GPhA’s Chairman of the Board of Directors from 2014 to February 2016.
He holds a BS and an MS degree in chemical engineering from Cornell University, and an MBA from the Wharton School of the University of Pennsylvania.
Mr. Wheeler serves as chair of the Science and Technology Committee and as member of the Compensation and Leadership Development Committee.